Navigation Links
Real Time Genomics Announces Formation of its Scientific Advisory Board
Date:3/7/2013

San Francisco, CA (PRWEB) March 07, 2013

Real Time Genomics, Inc., the genome analytics company, today announced the formation of its Scientific Advisory Board (SAB) to provide guidance and expertise as the company develops tools to improve the accuracy and utility of genomic sequencing in the research of human disease.

Founding members of the SAB include Dr. George Weinstock, Associate Director of The Genome Institute at Washington University School of Medicine, Dr. Timothy Triche, Director of the Center for Personalized Medicine at Children’s Hospital Los Angeles and the Associate Director of the Pediatric Institute of Molecular Medicine at Phoenix Children’s Hospital, and Dr. Gene Myers, Director of the Center for Systems Biology at the Max Planck Institute, Dresden.

“We are very pleased to welcome three scientists as talented as George, Tim and Gene to our SAB,” said Steve Lombardi, Chief Executive Officer of Real Time Genomics. “Their track records of success in their respective fields are exemplary and reflect their status as world-class genomics scientists. Their addition to the leadership of RTG greatly expands our knowledge of the progress and direction of the technology, science and medical vectors that influence the adoption of genomics to both life science research and personalized medicine.”

“Real Time Genomics has assembled a exceptional team of scientific, engineering, and business leaders all focused on delivering the most accurate and cost effective results for medical and biological application,” said Dr. Weinstock, who will Chair the Scientific Advisory Board. “Their platform has proven to be accurate, reliable and robust. I am pleased to join RTG’s scientific advisory board and look forward to guiding the company as it pursues its important mission.”

Dr. Weinstock applies high-throughput DNA sequencing, genome-wide analysis, bioinformatics, and other genetic methods in his role as Associate Director of the Genome Institute at Washington University. He is recognized worldwide as a leader of the Human Microbiome Project, studying the genomes of both host and microbiome organisms to characterize the communities they form and measure how communities change in different health and disease states. Previously, Dr. Weinstock was professor in the department of molecular and human genetics, the department of molecular virology and microbiology, and co-director of the Human Genome Sequencing Center of the Baylor College of Medicine. He was one of the leaders of the Human Genome Project and also of the first personal genome project, sequencing Dr. James Watson’s genome using next-generation sequencing technology. He received his B.S. degree from the University of Michigan in 1970 and his Ph.D. from the Massachusetts Institute of Technology in 1977.

Dr. Triche's research focuses on the genetic aspects of cancer biology. Combined with his record of success in leadership positions at CHLA and USC, he was appointed to the Directorship positions at CHLA and Phoenix Children's Hospital. He is also associated with the Children’s Oncology Group (COG), where he is presently a member of the executive committee, the scientific council and associate chair for translational research. Previously, he was chair of the Department of Pathology & Laboratory Medicine and pathologist-in-chief at Childrens Hospital Los Angeles, and a professor in the Department of Pathology & Laboratory Medicine and vice chairman of the Department of Pathology at the Keck School of Medicine at the University of Southern California. Prior to CHLA/USC, he served as the Chief of the Ultrastructural Laboratory of the Division of Pathology at the National Cancer Institute. He also serves as the Chief Medical Officer at NanoValent Pharmaceuticals, Inc., and previously was the Chairman and Chief Executive Officer of Oncormed, Inc. Dr. Triche received an A.B. from Cornell University in 1966, and in 1971 received both a Ph.D. in cell biology and an M.D. from Tulane University.

Dr. Myers is a pioneer in bioinformatics. Among his many accomplishments, he is best known as the creator of BLAST and the whole-genome shotgun protocol and assembler — which he applied while at Celera Genomics to assemble the human genome. More recently his research has focused on analyzing and extracting information from images obtained by various forms of microscopy. Previously, Dr. Myers was Group Leader, HHMI Janelia Farm Research Campus, Professor of Computer Science & MCB, UC Berkeley, and Vice President of Informatics Research, Celera Genomics. He received his Ph.D. in Computer Science from the University of Colorado, Boulder, and then moved to University of Arizona, Tucson, where he was Professor of Computer Science and Molecular and Cellular Biology before joining Craig Venter at Celera to tackle the largest shot-gun assembly project: the human genome.

About Real Time Genomics, Inc.
Real Time Genomics (http://www.realtimegenomics.com) has a passion for genomics. The company offers software tools and applications for the extraction of unique value from genomic data. Its competency lies in applying the combination of its patented core technology and deep computational expertise in algorithms to solve problems in next generation genomic analysis. Real Time Genomics is a private San Francisco based company backed by investment from Catamount Ventures, Lightspeed Venture Partners, and GeneValue Ltd.

Contact:
Steve Lombardi
President & CEO
650.872.0999

Read the full story at http://www.prweb.com/releases/2013/3/prweb10508275.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Real Time Genomics® Announces Platform Launch, Expanding Commercial Operations
2. TopCoders Open Community Challenge Process Yields 970 Fold Increase in Speed for Big Data Genomics Sequencing Algorithm
3. Boston Childrens Hospital announces international genomics competition winner
4. Law Office of Brodsky & Smith, LLC Announces Investigation of Complete Genomics, Inc.
5. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
6. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics: Twease.org
7. Rosetta Genomics Expands Management Team, Laboratory Capacities and Commercial Operations
8. Rosetta Genomics Receives 2012 North American Entrepreneurial Company of the Year Award by Frost & Sullivan
9. Rosetta Genomics Announces Closing of Public Offering of 5.5 Million Ordinary Shares
10. First Plant Genomics Yield Technology Progresses
11. Rosetta Genomics Pays Off Secured Loan and Reclaims Unencumbered Rights to All Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... SAN DIEGO , Feb. 12, 2016 Biocom, ... life science community, took a group of San ... as part of its 2016 Precision Medicine Advocacy Fly-In. ... at the Food and Drug Administration (FDA), the Centers for ... (NIH), as well as San Diego U.S. Representatives Susan ...
(Date:2/12/2016)... MedGenome,s Commitment Will Help ... of Complex Diseases Such as Cancer, Metabolic Disorders, ... --> --> MedGenome, the market ... leading provider of genomics research services globally, today ... GenomeAsia 100K consortium as a founding member. ...
(Date:2/11/2016)... Germany and GERMANTOWN, Maryland ... QGEN ; Frankfurt Prime Standard: QIA) today announced the ... Panels for gene expression profiling, expanding QIAGEN,s portfolio of ... panels enable researchers to select from over 20,000 human ... discover interactions between genes, cellular phenotypes and disease processes. ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... delivering cutting-edge information focused on the development and manufacture of biopharmaceuticals and ... premier sponsor of the 2016 BioProcess International Awards – Recognizing Excellence in ...
Breaking Biology Technology:
(Date:1/20/2016)... MINNETONKA, Minn. , Jan. 20, 2016   ... that supports the entire spectrum of clinical research, is ... in 2015. MedNet,s significant achievements are the result of ... of) iMedNet eClinical , it,s comprehensive, ... --> --> Key MedNet growth ...
(Date:1/15/2016)... , Jan. 15, 2016 Recent publicized ... small to find new ways to ensure data security ... iOS and Android that ties ... biometrics, transforming it into a hardware authorization token. Customer ... swipe their fingerprint on their KodeKey enabled device to ...
(Date:1/11/2016)... Jan. 11, 2016 Synaptics Incorporated (NASDAQ: ... today announced that its ClearPad ® TouchView ™ ... won two separate categories in the 8 th ... Best Technology Breakthrough. The Synaptics ® TDDI solution ... supply chain, thinner devices, brighter displays and borderless designs. ...
Breaking Biology News(10 mins):